Gland Pharma Approves $21M US Investment and Board Reconstitution
Gland Pharma Ltd 路 Others (Uncategorized) 路 01 Oct 2026, 9:15 pm
Gland Pharma Approves $21M US Investment and Board Reconstitution Gland Pharma approved a USD 21m cash investment in wholly-owned subsidiary Gland Pharma USA Inc. to subscribe to a 60% stake in newly incorporated Novelstar Pharma Inc. by 31st Oct'26, expanding its US footprint alongside Fosun Pharma USA Inc. (40% stake). Post-transaction, Novelstar will become a step-down subsidiary with USD 35m in share capital. Additionally, effective 1st Oct'26, Wenjie Zhang resigned as Non-Executive Director, and Xingli Wang was appointed as Additional Non-Executive Director, prompting reconstitutions across key board committees.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation 路 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs 路 16 Nov 2026
- Grant of Options to Purchase Securities 路 16 Nov 2026
- Q2FY27 Earnings Call Transcript 路 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company 路 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 路 09 Nov 2026
- Q2FY27 Earnings Call Recording 路 07 Nov 2026
- Q2Fy27 Investors presentation 路 06 Nov 2026
